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Prevention Of Opportunistic Infections (OIs)
In Those With HIV Infection
Prior to the availability of effective antiretroviral
therapy (ART), most patients with HIV infection
could expect to experience a fairly predictable
and inexorable decline in their CD4 count. Once
a patient’s CD4 count declines significantly, pro-
phylaxis for opportunistic infections is initiated
and continues indefinitely.  
Beginning in 1995, the availability of more effec-
tive protease inhibitor based ART forever altered
this algorithm. With more potent ART, many
patients experience significant and sustained
improvements in immunologic function as evi-
denced by CD4 count increases and in vitro
responses to antigenic stimulation. Soon the
question arose  whether those who during CD4
nadir met criteria for prophylaxis still required
such agents after experiencing ART-induced
immune reconstitution.
Initial anecdotal reports gave way to longer
observational trials. When last reviewed in
HEPP News,1 some data existed that supported
stopping primary and secondary prophylaxis in
the setting of sustained ART-induced CD4 count
increases. Subsequently, further information has
accumulated that has now lead to a revision in
the United States Public Health Services/
Infectious Diseases Society of America
(USPHS/IDSA) Guidelines for the Prevention of
Opportunistic Infections in HIV Infected Adults
and Adolescents. The revised version of these
recommendations, released November 28,
2001, is available at www.HIVATIS.org/trt-
gdlns.html. Some important aspects of these
guidelines will be summarized here.
Initiating Primary
Prophylaxis to Prevent OIs
The recommendations for prevention of disease
related to Pneumocystis carinii, Mycobacterium
tuberculosis, Mycobacterium avium complex,
Toxoplasma gondi, Streptococcus pneumonia,
Hepatitis A and B, influenza, and Varicella are
available and have not significantly changed
from the prior guidelines. Some are summarized
in Table 1 on page 2.
Initiating Secondary
Prophylaxis To Prevent OIs
After treatment of active disease, secondary pro-
phylaxis is recommended to prevent relapse of
many common OIs. These recommendations
are also not significantly changed from prior
USPHS/IDSA recommendations and are sum-
marized in Table 2 on page 4.
Criteria For Discontinuing
Primary And Secondary
Prophylaxis
For many of the most common OIs, data exists
to support the discontinuation of secondary pro-
phylaxis in those with sustained ART-induced
immunologic recovery. Such an approach car-
ries the potential for decreasing the potential for
side effects, drug-drug interactions, total pill bur-
den, and the significant costs associated with
some prophylactic medications. (Per annum
costs: clarithromycin 500 mg bid $2,843; flu-
conazole 200 mg qd $4,603; ganciclovir 1000
mg tid $17,794.)  Table 3 details updated recom-
mendations for starting, discontinuing, and
restarting primary and secondary prophylaxis for
some of the most devastating HIV associated
opportunistic infections. For many OIs, the evi-
dence for efficacy of continued prophylaxis
might not outweigh the potential adverse conse-
quences. 
Each patient must be approached on an individ-
ualized basis. Discontinuing prophylaxis carries
some risk for those patients who will not have
access to frequent medical evaluation and blood
test monitoring. In some such cases it may be
most prudent to continue prophylaxis until such
time as the patient can be monitored more close-
ly.
For patients who can be followed closely, data
support discontinuing primary prophylaxis in
those whose CD4 count in response to ART has
for at least 3 months remained >100
(Mycobacterium avium complex) or >200
(Pneumocystis, Toxoplasmosis).
If you have any problems with this fax transmission please call 800.748.4336 or e-mail us at HEPP@corrections.net
WHAT’S INSIDE
HEPPigram pg 5
Rapid Report pg 6
HIV 101 pg 7
Self-Assessment Test pg 9  
Joseph Bick, M.D.*, Director, HIV Treatment Services, California Medical Facility, Vacaville, CA, California DOC
HEPP
news
HIV & HEPATITIS 
EDUCATION
PRISON 
PROJECT
Sponsored by the Brown Medical School Office of Continuing Medical Education and the Brown University AIDS Program.
December 2001    Vol. 4, Issue 12
ABOUT HEPP
HEPP News, a forum for correctional
problem solving, targets correctional
administrators and HIV/AIDS and hepatitis
care providers including physicians, 
nurses, outreach workers, and case
managers. Continuing Medical Education
credits are provided by the Brown
University Office of Continuing Medical
Education to physicians who accurately
respond to the questions on the 
last page of the newsletter.  
CHIEF EDITOR 
Anne S. De Groot, M.D.
Director, TB/HIV Research Lab,
Brown Medical School
DEPUTY EDITORS
Frederick L. Altice, M.D.
Director, HIV in Prisons Program,
Yale University AIDS Program
Joseph Bick, M.D.
Director, HIV Treatment Services,
California Medical Facility,
California Department of Corrections
David P. Paar, M.D.
Director, AIDS Care and Clinical
Research Program, 
University of Texas, Medical Branch
Faculty Disclosure 
In accordance with the Accreditation Council
for Continuing Medical Education Standards
for Commercial Support, the faculty for this
activity have been asked to complete
Conflict of Interest Disclosure forms.
Disclosures are listed at the end of articles.
All of the individual medications discussed
in this newsletter are approved for treatment
of HIV and hepatitis unless otherwise indi-
cated. For the treatment of HIV and hepatitis
infection, many physicians opt to use combi-
nation antiretroviral therapy which is not
addressed by the FDA.
HEPP News is grateful for the support 
of the following companies through 
unrestricted educational grants:
Major Support: Agouron Pharmaceuticals,
Dupont Pharmaceuticals, and 
Roche Pharmaceuticals
Sustaining: Abbott Laboratories, 
Boehringer-Ingelheim/Roxane
Laboratories, and Schering-Plough
Supporting: Merck & Co. and
OrthoBiotech
Continued on page 2
For patients who have experienced active
disease due to Pneumocystis, Toxoplasma,
Mycobacterium Avium, Cryptococcus, and
Cytomegalovirus, criteria are provided for
the discontinuing of secondary prophylaxis
(see Table 3).  Again, this should be under-
taken on an individualized basis and only
after the patient is educated about the risks
and benefits involved with each approach.
For some patients, the ability to be reward-
ed for good ART adherence by stopping
prophylactic medications may serve as an
additional incentive to continue to comply
with ART.
Risk Avoidance: Sexual
and Injection Drug
Exposures
Recommendations intended to help HIV
infected individuals avoid exposure to or
infection with opportunistic infections is
provided and categorized by risk group.
Clearly, at least some prisoners will contin-
ue to be sexually active while incarcerated
and some will engage in injection drug use
(IDU).  In spite of the fact that both activities
are prohibited in correctional facilities,
patients need more educational information
than “just say no.”  Sexual and IDU absti-
nence is the safest option for those inter-
ested in reducing the risk for acquisition of
CMV, HSV, HPV, HHV8, other HIV strains,
HAV, HBV, HCV and a variety of other
enteric pathogens. Acknowledging that risk
behaviors continue during incarceration,
prisoners should be provided harm reduc-
tion educational information detailing how
to decrease health risks if they choose to
continue to be sexually active and/or
engage in IDU.  Patients should be instruct-
ed about which sexual practices carry the
greatest health risks to them and their part-
ners.  To decrease the risk for enteric infec-
tions such as cryptosporidium, salmonella,
shigella, campylobacter, amebiasis, giar-
diasis, and hepatitis A, patients should
avoid sexual practices that might result in
oral exposure to feces. All non-immune
prisoners should be offered vaccination for
hepatitis B.  Non-immune IDUs and men
who have sex with men should be offered
vaccination for hepatitis A.  In those sys-
tems in which they are available, prisoners
should use latex condoms during every act
of sexual intercourse. [As this issue of
HEPP News went to press, the Los
Angeles county jail joined a handful of cor-
rectional facilities in this country that make
condoms available to prisoners].
Prisoners with a history of IDU should be
provided substance abuse treatment, and
linked to community services at the time of
parole.  Recognizing the reality that many
individuals will relapse to IDU during or fol-
lowing incarceration, patients should be
educated to never share or re-use
syringes, needles, or drug preparation
equipment.  Those who will be re-using
injection equipment should be advised to
clean all materials with bleach and water.
Furthermore, inmates should be educated
on syringe availability and encouraged to
use services such as pharmacy purchase
and needle exchange where available, and
to explore the possibility of physician pre-
scription when other services are not avail-
able.3 Non-immune IDUs should be vacci-
nated for hepatitis A and B. 
Risk Avoidance:
Occupational Exposures
HIV infected prisoners do hold jobs while
incarcerated that can place them at risk for
significant OIs. Those working in sanitation,
janitorial or laundry positions can come into
contact with body wastes, contaminated
sharps, and other materials that can trans-
mit diseases. All such workers should be
provided personal protective equipment
and educated in its use. All non-immune
workers should be offered vaccination
against hepatitis A and B. As a rule, prison-
ers should not be involved in direct patient
care.  In those systems that allow such
work, inmate workers should be provided
hepatitis B vaccination.
In areas endemic for histoplasmosis, HIV
infected prisoners should avoid activities
that are associated with an increased risk
for infection with this organism. Examples
include cleaning or remodeling old build-
ings, disturbing the soil beneath bird roost-
ing sites, and cleaning chicken coops.
Similarly, in areas endemic for coccid-
ioidomycosis, patients should avoid exten-
sive exposure to disturbed native soil as
might occur during agricultural work or
building excavation.
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Opportunistic Infections...
(continued from page 1)
Continued on page 4
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Table 1: Opportunistic Infection Prophylaxis to Prevent First Infection
(Strongly recommended standard of care)2
Pathogen
Pneumo-
cystis
carinii
Toxo-
plasma
gondii
Mycobac-
terium
avium 
complex
Varicella
Zoster
Virus (VZV)
Indication
CD4+ count
<200/µ L or
oropharyngeal
candadiasis
IgG antibody
to Toxoplasma
and CD4+
count <100/µ L
CD4+
count<50/µ L
Significant
exposure to
chicken pox or
shingles for
patients who
have no histo-
ry of either
condition, or, if
available, neg-
ative antibody
to VZV
First Choice
Preventive
Regimen
Trimethoprim-
sulfamethoxa-
zole (TMP-SMZ)
1 DS or SS po
qd (AI)
TMP-SMZ 1 DS
po qd (AII)
Azithromycin‡
1200 mg po qw
(AI), or clar-
ithromycin 500
mg po bid (AI)
Varicella zoster
immune globulin
(VZIG) 5 vials
(1.25 mL each)
im, administered
<96 h after
exposure, ideally
within 48 h (AIII)
Alternative Preventive Regimen
Dapsone 50 mg po bid or 100mg po
qd (BI); dapsone 50 mg po qd plus
pyrimethamine 50 mg po qw plus
leucovorin 25 mg po qw (BI); dap-
sone 200 mg po plus pyrimethamine
75 mg po plus leucovorin 25 mg po
qw (BI); aerosolized pentamidine 300
mg q month via Respirgard II nebu-
lizer (BI); atovaquone 1500 mg po qd
(BI); TMP-SMZ 1 DS po tiw (BI)
TMP-SMZ 1 SS po qd (BIII); dap-
sone 50 mg po qd plus
pyrimethamine 50 mg po qd plus leu-
covorin 25 mg po qw (BI); ato-
vaquone 1500 mg po qd with or with-
out pyrimethamine 25 mg po qd plus
leucovorin 10 mg po qd (CIII)
Rifabutin 300 mg po qd
(CI);azithromycin 1200 mg po qw
plus rifabutin 300 mg po qd.
Ratings:  
A. Should always be offered  
B. Should generally be offered  
C. Optional  
D. Should generally NOT be
offered
E. Should NEVER be offered   
Quality of Evidence:  
I. Evidence from at least one properly randomized, controlled trial  
II. Evidence from at least one well-designed clinical trial without randomization, from
cohort or case-controlled analytic studies (preferably from more than once center), or
from multiple time-series studies. Or dramatic results from uncontrolled experiements.  
III. Evidence from opinions of repsected authorities based on clinical experience, descrip-
tive studies, or reports of expert committees.
Dear HEPP News Readers,
This month, HEPP is addressing opportunistic infections and fevers of unknown origins. As
the treatment of HIV has improved over the years, what we consider opportunistic infections
has shifted considerably. Dr. Bick has done his usual excellent job in presenting our current
and past thoughts on OIs. Although previous issues have discussed it, hepatitis is rapidly
becoming our most lethal co-infection. More and more authors are including hepatitis as an
opportunistic infection. Likewise, more and more correctional systems are having to face the
reality of hepatitis C in their populations. All of us will be significantly relieved when we have
better treatment regimens for this disease complex, especially the genotype 1 series that is
so prevalent in our environment.  
We all hope that with better and better control of HIV disease, with mechanisms to make
sure our patients get every dose every time, with newer and easier regimens, and with more
potent anti-virals, that opportunistic infections that plagued us just five years ago and
destroyed our patients’ lives and quality of life, will be a distant medical memory. In some
significant sized systems, there has not been a case of CMV retinitis in over two years.
Although it will be unlikely because of late diagnoses in some of our patients, hopefully PCP
pneumonia and Mycobacterium avium complex will become important only in the history of
medicine textbooks.
Fevers of unknown origin (FUO) is a very complex subject that is addressed very succinct-
ly in this issue. The challenges presented by a patient with an FUO are enough to make the
hardiest diagnostician quake, especially when other signs and symptoms, laboratory analy-
ses, and radiography are not helpful.  
After reading this issue, health care providers should understand the steps involved in work-
ing-up a fever of unknown origin and the various treatment regimens recommended for
opportunistic infections.
Please enjoy this issue. Not only is it another intellectually stimulating and challenging pre-
sentation, but this journal touches us all right where we live. It is so relevant to our daily
lives. The authors and editors have done a great job in making this journal the top of the line
in its field.              
Sincerely,
David Thomas, M.D.
Letter from the Editor
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4Risk Avoidance: Food
Related Exposures
Prisoners commonly store food in their cells,
and rarely have access to refrigeration or a
way to reheat leftovers.  Patients should be
warned about the risks associated with eat-
ing food that has been improperly stored or
cooked.  Prisoners may receive food during
visits or in packages from home. Soft
cheeses such as Mexican style queso fresco
carry a risk for listeriosis and should be
avoided by those who are HIV infected.
Correctional staff should routinely monitor
the facility’s kitchen practices to ensure that
all meat and poultry are appropriately
cooked (to an internal temperature of 180°
for poultry, and 165°  for meat.)  All produce
should be washed, and procedures should
be in place to ensure that uncooked meat
and poultry does not come into contact with
other foods. All counters, cutting boards,
knives, and utensils should be thoroughly
cleaned after being used to prepare
uncooked meat, poultry, and fish.  Although
there is no medical justification for the exclu-
sion of those with HIV, hepatitis B, or hepati-
tis C from working in food service, those with
diarrhea, open lesions on their hands or
arms, or acute hepatitis A should not work as
food handlers.  Providers may consult the
NCCHC guidelines, including  “P-16: Kitchen
Sanitation and Food Handlers” for further
recommendations.
In conclusion, HIV-infected prisoners are at
significant risk for a wide variety of OIs.
Information exists which can assist our
patients to avoid exposure to and infection
with many of these organisms. Through
patient education and the appropriate use of
immunizations, morbidity and mortality due
to OIs can be avoided.  Data are also accu-
mulating to support the discontinuation of OI
prophylaxis in those who have experienced
ART-induced immunologic recovery. The
USPHS/IDSA guidelines provide guidance to
clinicians and patients who are considering
withdrawing preventive therapy for the most
common OIs.
Opportunistic Infections...
(continued from page 2)
December 2001     Volume 4, Issue 12 visit HEPP News online at www.hivcorrections.org
*Nothing to disclose.
‡ During pregnancy, azithromycin is recommended
instead of clarithromycin due to the teratogenicity
of clarithromycin in animals.
References:
1. “Prevention of Opportunistic Infections.”
HIV101, HEPP News.  2000 October.
2. 2001 USPHS/IDSA Guidelines for the
Prevention of Opportunistic Infections in Persons
Infected with Human Immunodeficiency Virus. On
the web at http://www.hivatis.org/guidelines/other/
OIs/OIGNov27.pdf
3. Burris et al. Ann Intern Med. 2000;133:218-226.
Table 3: Guidelines for Discontinuing and Restarting Primary and
Secondary Prophylaxis for Opportunistic Infections2
Table 2: Prophylaxis to Prevent Recurrence of Opportunistic Disease
in Adults (Secondary Prophylaxis)
Oppor-
tunistic
Infection
Pneumo-
cystis
carinii
Pneumo-
nia
Toxo-
plasma
Myco-
bacterium
avium 
complex
Cyto-
megalo
virus
retinitis
Crypto-
coccosis
Indications
for
Discontinuing
10 Prophylaxis
CD4+ >200
cells/µL for >3
months (AI)
CD4+ >200
cells/µL for >3
months (AI)
CD4+ >100
cells/µL for >3
months (AI)
Not applicable
Not Applicable
Indications
for Restarting
10 Prophylaxis
CD4+ <200
cells/µL (AIII)
CD4+ <100-200
cells/µL (AIII)
CD4+ <50-100
cells/µL (AIII)
Not applicable
Not Applicable
Indications
for Discontin-
uing 20
Prophylaxis^
CD4+ >200
cells/µL for >3
months (BII)
CD4+ >200
cells/µL sus-
tained (>6 mo)
and completed
initial therapy
and asympto-
matic for toxo
(CIII)
CD4+ >100
cells/µL sus-
tained (>6 mo)
and completed
12 mo of MAC
therapy and
asymptomatic
for MAC (CIII)
CD4+ >100-150
cells/µL sus-
tained (>6 mo)
and no evidence
of active disease
and regular
opthalmic exami-
nation (BII)
CD4+ > 100-200
cells/µL sus-
tained (6 mo)
and completed
initial therapy
and asym-
potamtic for
cryptococcosis
(CIII)
Indications
for Restarting
20 Prophylaxis
CD4+ <200
cells/µL (AIII)
CD4+ <200
cells/µL (AIII)
CD4+ <100
cells/µL (AIII)
CD4+ < 100-150
cells/µL (AIII)
CD4+ < 100-200
cells/µL (AIII)
^ After active disease.
Pathogen
Pneumocystis
carinii
Toxoplas-
mosis gondii
Mycobac-
terium avium
complex
Cytomegalo-
virus
First Choice Preventive
Regimen
Clarithromycin‡ 500 mg po bid (AI)
plus ethambutol 15 mg/kg po qd
(AII); ± rifabutin 300 mg po qd (CI)
Ganciclovir 5-6 mg/kg/day iv 5-7
days/wk or 1000 mg po tid (AI);
foscarnet 90-120 mg/kg iv qd (AI);
(for retinitis) ganciclovir sustained-
release implant q 6-9 mo plus
ganciclovir 1.0-1.5 g po tod (AI)
Azithromycin 500 mg po qd (AII)
plus ethambutol 15 mg/kg po qd;
± 300 mg po qd (CI)
Cidofovir 5 mg/kg iv qow +
probenecid 2 g po 3 h before the
dose followed by 1 g po 2 h after
the dose  and 1 g po 8 h after the
dose (total of 4 g) (AI); fomivirsen
1 vial (330 mg) injected into the
vitreous then repeated every 2-4
wks (AI); valganciclovir 900 mg
po qd (BI)
same as primary prophylaxis; see Table 1
same as primary prophylaxis; see Table 1
Alternative Preventive
Regimens
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HEPPigram: Management of Fever of Unknown Origin 
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IV line or neutropenia (<500/mm2)
NO
Consult appropriate algorithm:
 Headache, neurological
symptoms: neurologic algorithm
 Cough, dypsnea: pulmonary
algorithm
 Diarrhea: diarrhea algorithm
Other focal findings:
 Nasal symptoms: evaluate
for sinusitis
 IV line: blood cultures +
antibiotics ± line removal with
roll culture
 Soft tissue inflammation:
aspirate/biopsy for culture, CT
scan
 Adenopathy: lymph node
biopsy/aspirate
 Abdominal pain: LFTs, amy-
lase, CT scan
Review medications and
confirm fever
Blood cultures,
CBC, Liver Function Tests
(LFTs), Chest X-ray
YES
Drug holiday
No
response
Responds to
discontinua-
tion of agent
NO
No drug cause: Initial
Evaluation 
*Screening Tests:
 CBC, differential, CD4 count
 Chemistry panel, LDH
 Urine culture and analysis
 Blood culture
 PPD and anergy screen
 CD4 count <300/mm3;
mycobacterial blood culture and
serum cryptococcal antigen
Chest x-ray±blood
gasses/oximetry
Patient Receiving Drugs
Likely to Cause Fever:
Common: Sulfonamides,
Dapsone, Amphotericin
B, Phenytoin, Penicillins,
Barbiturates, Bieomycin,
Carbemazepine,
Thalidomide,
Pentamidine,
Clindamycin
Less Common:
Salicylates,
Cephalosporins, INH.
Rifampin, Streptomycin,
PAS, Cocaine products,
Azathioprine
YES
While waiting for results, treat with 
empiric antibiotics + G-CSF
Responds and/or blood
culture positive 
No response and 
cultures negatives
Screening tests *
Next Round of Tests:
 Evaluate for TB: cul-
ture sputum, urine
 CT scan abdomen,
chest±head
 Histoplasmosis:
Antigen assay blood and
urine
 Lumbar puncture: CSF
analysis
 Evaluate sinusitis and
dental source
 Lymphoma: Node
biopsy, LDH, liver/mar-
row biopsy
 Biopsy liver (rarely pos
with normal LFTs)
 Gallium scan, indium
WBC scan; rarely useful
 Biopsy marrow: yield
lower than liver biopsyLFTs abnormal:
Cholestasis changes:
ultrasound or CTERCP
or biopsy Granulomas:
M. avium, TB, histoplas-
mosis
Cholangiopathy: CMV,
cryptosporidia,
microsporidia, lym-
phoma, KS, idiopathic
(30%)
Hepatocellular: hepatitis
viruses
ETOH, drug-induced,
CMV, HSV
M. avium bacterium
(most common cause
FUO) Treat
Crypt Ag posi-
tivelumbar
puncture and
treat
Cytopenia
bone marrow
aspirate/biopsy
Abnormal
chest x-ray or
hypoxemia
pulmonary
algorithm
Treat
Positive Negative
Adapted from Bartlett JG, Gallant JE.  2001-2001 Medical Management
of HIV Infection.  Johns Hopkins University, Baltimore, MD 2001 (356).
*Screening Tests:
 CBC, differential, CD4 count
 Chemistry panel, LDH
 Urine culture and analysis
 Blood culture
 PPD and anergy screen
 CD4 count <300/mm3; mycobacterial
blood culture and serum cryptococcal anti-
gen Chest x-ray±blood gasses/oximetry
Rapid Report: NCCHC Shines in New Mexico
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The 25th National Conference on Correctional Health Care ended
last month in Albuquerque, NM. The weather cooperated nicely and
a string of beautiful days in very pleasant surroundings enhanced
this premier correctional health care meeting, which lasted from
November 10 through 14, 2001. Total attendance was close to the
2,000 mark. 
Prior to the conference proper, there were a number of seminars
including an in-depth look at the NCCHC Standards, a meeting of the
Society of Correctional Physicians, and a well-attended HEPP sym-
posium entitled “Bridging the Gap: Getting High Risk Patients into
Treatment.” The HEPP meeting covered current topics in infectious
disease in corrections including the outbreak of hepatitis B in the
Georgia Department of Corrections. Dr. Joseph Paris from the
Georgia Department of Corrections related the episode, presenting
Dr. Amy Kahn's, Centers for Disease Control, findings. 
Dr. Paris stated that following the discovery of an acutely jaundiced
male in a Georgia prison, the CDC interviewed and tested potential
contacts at the same dormitory and was able to initially uncover an
additional group of 5 more inmates acutely infected with hepatitis B
but completely asymptomatic. Additional interviews and testing of the
remainder of the prison population revealed the presence of another
group of 5 acutely infected, asymptomatic hepatitis B patients. None
of the 11 developed serious complications of hepatitis B. Risk factors
for intramural transmission of hepatitis B in the prison settings were
tattooing, homosexual sex, and body fluid exposures in general,
activities that are clearly not condoned by the Georgia DOC. 
This was the first completely documented example of intramural
transmission of hepatitis B in prison settings.  Furthermore, it seems
that for every overt, symptomatic acute hepatitis B case, one would
expect the presence of 10 more cases.  However, testing and inter-
viewing in a timely manner are necessary to discover these cases.
Vaccination of the susceptible inmates did take place at the Georgia
prison, but vaccination for the entire state prison population has not
yet occurred; however, a budget for that purpose was requested by
Dr. Paris and is being considered by the Appropriations Committee
of the Georgia legislature.
A companion presentation on the national picture on inmate risk of
hepatitis B was given by another of the CDC researchers involved in
the outbreak, Dr. Robert Lyerla. Additional presentations at the HEPP
symposium included a discussion of tuberculosis in corrections as
presented by Dr. Anne De Groot, which highlighted the TB situation
in prisons with “real life lessons” learned from TB outbreaks in New
York, South Carolina, and California. Dr. De Groot also gave a talk
on HIV-infected women, highlighting the differences in the way HIV
affects women and men including the new information on differences
in viral load between men and women when they progress to AIDS. 
Dr. Joe Bick of the California Department of Corrections gave a pre-
sentation entitled “Getting Transgendered Patients into Treatment” in
which he explained the issues these patients face and described how
their gender identification affects their HIV treatment.
Dr. Eric Avery, a psychiatrist from the University of Texas Medical
Branch in Galveston, presented the various anti-depressant medica-
tions available along with their side effects. He also described how
mental health and HIV treatment information must be available in pic-
torial form for incarcerated patients, as many of them do not read.  
Dr. Michael Wong also gave a comprehensive presentation on
Hepatitis C virus (HCV) in corrections at the HEPP symposium.  Dr.
Wong presented HCV as a single infection as well as the interaction
of HCV and HIV in a coinfected individual. 
During the Conference proper, there were Plenary Sessions and
Concurrent Sessions including HCV-related sessions delivered by
Newton Kendig, MD Arthur Brewer, MD, Berel Arrow, MD, Joseph
Paris MD, and Anne Spaulding MD; HIV-related sessions delivered
by Bill Ruby, DO, John Bartlett, MD, and David Thomas, MD; a ses-
sion describing Research in Corrections by Thomas Conklin, MD;
sessions describing legal issues delivered by Roderic Gottula, MD,
William Rold, JD; a session on Oral Health presented by Thomas
Shields, DDS and John Battle, DMD; a session on Diabetes
Monitoring presented by Michael Puerini, MD; and a session on
Correctional Physician Productivity presented by Joseph Paris, MD.
Other concurrent sessions tackled important issues in Nursing,
Pharmacy, Mental Health, Education, Juvenile Offenders, Female
Prisoners, Medical School Involvement, among others. The
Conference provided a veritable cornucopia of timely topics and
attendees had to make agonizing choices between outstanding,
simultaneous sessions. 
The next NCCHC Meeting will be held in October 19-23, 2002, in
Nashville, Tennessee.
*Nothing to disclose.
**Nothing to disclose.
By Joseph Paris, M.D.*,  Medical Director, GA Department of Corrections, Rebecca Nerenberg**, Managing Editor, HEPP News
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Resources & Websites
Powerpoint presentations from the HEPP NCCHC preconference
symposium available in electronic form. Topics include: the correction-
al side of HCV, HBV, TB, HIV in women, Mental Health in HIV-positive
patients, and information on treating transgendered patients.  Email
HEPPNews@brown.edu
Opportunistic Infections
USPHS/IDSA Opportunistic Infection Treatment Guidelines
http://www.hivatis.org/guidelines/other/OIs/OIGNov27.pdf 
AEGIS Information on Opportunistic Infections
http://www.aegis.com/topics/oi/
AIDS Treatment Data Network Definitions of OIs
http://www.aidsinfonyc.org/network/oisgloss.html
CDC Fact Sheets on Drug Users in the US Criminal Justice
System
http://www.cdc.gov/idu/criminaljustice.htm
Canadian HIV/AIDS Legal Network
Background and Information sheets available on testing of persons
believed to be the source of an occupational exposure to HBV, HCV,
or HIV.  In English and French at
http://www.aidslaw.ca/Maincontent/issues/testing.htm
HIV/AIDS Annual Update 2001
A collection of 11 clinical reviews now available on Medscape.
http://hiv.medscape.com/update2001
HIV Treatment
AMFAR HIV/AIDS Treatment Directory, Summer 2001 Edition
For free copies, contact Barbara Good at barbara.good@amfar.org or
fax a request to 212.806.1601
Updated Adult and Adolescent HIV Treatment guidelines
http://www.hivatis.org/guidelines/adult/Aug13_01/pdf/AAAug13S.PDF
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1 Treatment of Opportunistic Infections  
The following are recommended as standard of care.1,2
Preferred Treatment
 Trimethoprim (TMP) 15 mg/kg/day + sulfamethoxazole
(SMX)75mg/kg/day PO or IV x 21 days in 3-4 divided
doses (typical oral dosage is 2 DS tid)
 Pyrimethamine 100-200 mg loading dose; then 50-100
mg/day PO + folinic acid 10mg/day PO + sulfadiazine or
trisulfapyrimidime 4-8 g/day PO for at least 6 weeks   
 Clarithromycin 500 mg PO bid plus Ethambutol (EMB)
15 mg/kg/day PO
Dermatomal:
 Acyclovir 800 mg PO 5x/day at least 7 days (until
lesions crust) or famciclovir 500 mg PO tid or valacyclovir
1 g PO tid x >7 days 
Disseminated, opthalmic nerve involvement or visceral:
 Acyclovir 30-36 mg/kg/day IV at least 7 days 
Acyclovir-resistant strains:
 Foscarnet 40 mg/kg IV q8h or 60 mg/kg q12h
 Intraocular ganciclovir implant (Vitrasert) q6
months+oral valganciclovir 900 mg/day
 Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h x 14
to 21 days
 Ganciclovir 5 mg/kg IV bid x 14 to 21 days
 Valganciclovir 900 mg PO bid x 21 days, then 900
mg/day
 Cidofovir 5 mg/kg IV q week x2, then 5 mg/kg q 2
weeks + probenecid, 2 g PO 3 hours before each dose, 
1 g PO at 2 and 8 hours post dose (total of 4 g) 
Mild:
 Acyclovir 400 mg PO tid or famciclovir 250 mg PO tid
or valacyclovir 1.0 g PO bid; all given for 7 to 10 days
Severe or Refractory:
1. Acyclovir up to 800 mg PO 5x/day or 
15-30 mg/kg/day IV at least 7 days                                
2. Valacyclovir 1 g PO bid-tid
Alternative Treatment
 TMP15mg/kg/day PO + dapsone 100mg/day PO x 21 days
 Pentamidine 4mg/kg/day IV x 21 days (often reserved for
severe cases)
 Clindamycin 600mg IV q8h or300-450mg PO q6h + pri-
maquine 30 mg/day base PO x 21 days
 Atovaquone 750mg suspension PO with meal bid x 21 days
 Trimetrexate 45 mg/m2/day + folinic acid 20 mg/m2 or IV
q6h
 Pyrimethamine + folinic acid (see preferred regimen) + clin-
damycin 900-1200* mg IV q6h or 300-450 mg PO q6h for at
least 6 weeks
 Pyrimethamine and folinic acid (see preferred regimen)
plus one of the following: azithromycin 1200-1500 mg/day,
clarithromycin 1 g bid, or atovaquone 750 mg qid with food
 Azithromycin + 900 mg PO x 2 first day, then 1200
mg/day x 6 weeks, then 600 mg/day (patients <50
kg receive half dose) (salvage therapy)
 Azithromycin 600 mg/day PO in place of clarithrmycin +
Ethambutol (EMB) ± Rifabutin (RFB) (same doses)
 Combination treatment with amikacin 10-15 mg/kg/day IV
or ciprofloxacin 500-700 mg bid
Dermatomal:
 Acyclovir 30 mg/kg/day IV
 Foscarnet 40 mg/kg IV q8h or 60 mg/kg IV q12h
Disseminated, opthalmic nerve involvement or visceral:
 Foscarnet 40 mg/kg IV q8h or 60 mg/kg IV q12h   
Acyclovir-resistant strains:
 Cidofovir IV
 Topical trifluridine
 Alternating or combining foscarnet and ganciclovir
 Intraocular injections of foscarnet 1.2-2.4 mg in 0.1 mL (N
Engl J Med  1994;330:868) or ganciclovir 2000 µg in 0.05-0.1
mL (Br J Ophthal 1996;80:214).
 Fomivirsen, 330 mg by intravitreal injection day 1 and 15,
then monthly  
Severe or Refractory:
 Foscarnet 40 mg/kg IV q8h or 60 mg/kg q12h x 3 weeks
 Topical trifluridine as 1% ophthalmic solution q8h
Alternative topical agents:
 Cidofovir 3% and foscarnet 1% cream
 Cidofovir 5 mg/kg q 2 weeks (limited experience)
By Rebecca Nerenberg^, Managing Editor, HEPP News
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*Initital Treatment Recommendations of the IAS-USA (Arch Intern Med 1998;158:957).  For information on maintenance and
other forms of therapy, consult reference below.  
^Nothing to disclose.
References:
1. Bartlett JG and Gallant JE.  2001-2002 Medical Management of HIV Infection, Chapter 5.  Johns Hopkins University,
Baltimore, MD. 2001.
2. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human
9th Conference on Retroviruses
and Opportunistic Infections
February 24-28, 2002
Seattle, Washington
Registration: Dec. 10, 2001-
Jan. 23, 2002
Call: 703.535.6899
Visit: www.retroconference.org
2002 National STD Prevention
Conference
March 4-7, 2002
San Diego, California
Fee: before Feb. 8: $140; 
after Feb. 8: $165
Visit: http://www.stdconference.org/
Call: Glenda Vaughn,
404.639.8260
Email: ghv1@cdc.gov
14th National HIV/AIDS Update
Conference (NAUC)
March 19-22, 2002
San Francisco, California
Sponsored by (amfAr) American
Foundation for AIDS Research
Fee: Before Dec. 15: $275; 
Dec 15-March 1: $325; 
After March 1: $375 
(special rates available)
Visit: http://www.amfar.org/cgi-
bin/iowa/nauc/index.html
CME credit available
International Conference on
Emerging Infectious Diseases
(ICEID)
March 24-27, 2002
Atlanta, Georgia
Visit: http://www.cdc.gov/iceid/
Email: cas1@cdc.gov
Clinical Updates in Correctional
Health Care
April 13-16, 2002
Fort Lauderdale, Florida
Fee: before Feb. 15, 2002: $175
Academy members, $250 non-
Academy members; after Feb. 15,
2002: $225 Academy members,
$300 non-Academy members
Visit: www.ncchc.org
Fax: 773.880.2424
XIV International AIDS
Conference
July 7-12, 2002
Barcelona, Spain
Fee: before Feb. 1, 2002: $850;
Feb.1-May 1, 2002: $950; after
May 1, 2002: $1,050
Visit: www.aids2002.com
Email: aids2002.registration@
congrex.se
Save the 
Dates
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Tacoma-Pierce County Proposes Mandatory
Testing of Inmates
Associated Press, 11/19/01
The director of the Tacoma-Pierce County
Health Department in Washington, Dr.
Frederico Cruz-Uribe, has proposed that all jail
inmates arrested on drug- or sex-related
charges be tested for HIV.  Dr. Cruz-Uribe has
proposed that these inmates, along with preg-
nant women and inmates who present with
symptoms of STDs during a doctor’s visit, be
required to undergo HIV testing. Those who
test positive would then be offered counseling
and treatment advice; their sexual and needle-
sharing partners would be notified. Although
some experts support the proposal, likening the
situation to the eradication of smallpox, other
experts believe these policies undermine civil
rights and that such a policy would not hold up
in court.
New Zidovudine Resistant HIV Found in
Treatment-Naïve Patients
PNAS. 2001; 98:24 (13907-13912).
Researchers from the CDC have detected a
distinct group of HIV-1 viruses in 3.3% of treat-
ment naïve, newly diagnosed HIV-1 positive
patients. These viruses have mutations in the
reverse transcriptase region of the genome that
make these viruses more likely to develop
drug-resistant mutations. These mutations are
different from those known to cause zidovudine
resistance, but indicate a significant potential
for zidovudine (AZT) and possibly stavudine
(d4T) resistance. This is especially troubling
because zidovudine is commonly used in drug
cocktails, experts report. Multi-drug resistant
viruses will have a negative impact on the inci-
dence of HIV and AIDS cases.
Connecticut to Begin HIV Tracking by Name
Hartford Courant, 11/7/01
The Connecticut Department of Public Health
will begin gathering data, including names, of
HIV-positive adults in order to track these indi-
viduals. Individuals do have the option to
request anonymity. Health care providers and
clinics will have the responsibility of informing
patients of that option. Although the state com-
missioner of public health believes that this new
plan serves the needs of the HIV-positive com-
munity, other experts claim that the new system
will discourage some individuals from seeking
testing.
HIV Viral Load in Genital Tract and Blood
Not Parallel
Lancet 2001;  358: 9293 (1593-1601).
A study from the Women’s Interagency HIV
Study cohort reports that women who have low
levels of HIV in their blood may still have high
levels of virus in their genital tracts. One-third of
women whose blood viral load was lower than
500 copies/mL still had high levels of HIV in
their genital tracts and experienced genital tract
viral shedding, increasing the rate of transmis-
sion through sexual encounters and pregnan-
cies. Some experts believe that genital tract
HIV levels may better estimate the chances of
HIV transmission.
Hepatitis
Oregon Inmates Sue for Hepatitis C
Treatment
Portland Oregonian, 11/2/01
A group of 11 inmates in Oregon have filed suit
against the state Department of Corrections
over the state’s treatment of inmates with
hepatitis C. The group of inmates from the
Salem, Oregon State Penitentiary are claiming
that the policies of the DOC exclude inmates
from HCV treatment and testing. The inmates
are seeking $17.5 million for the treatment of
HCV-positive inmates and mandatory testing of
all new inmates. Corrections officials do not
believe the inmates will win the suit, explaining
that no system in the country has a similar pol-
icy. 
Tuberculosis
Recurrent TB Infection More Likely in HIV-
positive Patients
Lancet, 2001; 358: 9294.
A study of goldmine workers in South Africa has
revealed that HIV-positive individuals were
more likely to experience recurrent tuberculosis
(TB) infection, even after successful completion
of TB therapy.  Approximately 27% of the HIV-
positive mineworkers experience recurrence of
TB compared to 13.7% of the HIV-negative par-
ticipants.  Recurrence due to relapse was more
common in the HIV-negative participants, while
recurrence due to reinfection was more com-
mon among the HIV-positive participants.
However, there was a large number of cases
for which the cause of recurrence was unknown
among the HIV-positive participants.  HIV infec-
tion was shown to be the most significant risk
factor for reinfection with TB, according to the
study.
News Flashes
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CORRECTION:
The titles of the Nelfinavir and Amprenavir
columns in the November 2001 HIV 101
were swapped. The information under the
Nelfinavir column applies to the drug
Amprenavir, and vice versa. The new ver-
sion of the November 2001 issue with the
correct table is now available online at
http://www.hivcorrections.org. The entire
table will be reprinted in the January 2002
edition of HEPP News.  
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through June 30, 2002. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. True or False:
There is now data that support the discontinuation of secondary OI
prophylaxis in those patients who experience sustained ART-
induced immunologic recovery.
(a) True
(b) False
2. In areas endemic to histoplasmosis, which of the following activi-
ties should HIV-positive prisoners avoid?
(a) cleaning chicken coops
(b) folding laundry
(c) disturbing the soil beneath bird roosting sites
(d) cleaning or remodeling old buildings
(e) a, c, and d
3. Which of the following are screening tests that should be per-
formed in the work-up of a fever of unknown origin?
(a) CBC
(b) urine culture
(c) blood culture
(d) liver function tests (LFTs)
(e) all of the above
4. If a patient experiences a fever whose origin is unknown, and is
receiving dapsone as part of a treatment regimen, what should be
the physician’s next step?
(a) take a chest x-ray
(b) put the patient on a “drug holiday”
(c) put the patient on empiric antibiotics
(d) treat the patient with penicillin
(e) perform a CT scan of the abdomen and/or the head
5. What is the preferred treatment regimen for treating a mild her-
pes simplex infection in an HIV-positive patient?
(a) acyclovir 400 mg PO tid for 7-10 days
(b) acyclovir 800 mg PO tid for 7-10 days
(c) no treatment recommended
(d) valacyclovir 1 g PO bid
(e) acyclovir 400 mg PO bid for 7-10 days
6. Which of the following is (are) a preferred treatment regimen(s)
for treating Cytomegalovirus retinitis infection?
(a) Intraocular ganciclovir implant q6 months + oral 
valganciclovir 900 mg/day
(b) Valganciclovir 900 mg PO bid x 21 days, then 900 mg/day
(c) Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h x 14 to 
21 days
(d) Cidofovir 5 mg/kg 1V q week x2, then 5 mg/kg q 2 weeks + 
probenecid, 2 g PO 3 hours before each dose, 1 g PO at 2 and 
8 hours post dose
(e) all of the above
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HIV 101 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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